Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 1 (4), FSO73

The Case of Galantamine: Repurposing and Late Blooming of a Cholinergic Drug


The Case of Galantamine: Repurposing and Late Blooming of a Cholinergic Drug

Hermann Am Mucke. Future Sci OA.


Galantamine is a reversible inhibitor of cholinesterases and an allosteric modulator of neuronal nicotinic acetylcholine receptors which restores reduced cholinergic tone in the central and peripheral nervous system. Characterized in the early 1950s in Bulgaria, it saw limited use for paralytic and neuropathic conditions until the cholinergic hypothesis of Alzheimer's disease opened totally new perspectives for its utility. Although constricted supplies at extremely high prices and a fragmented patent situation made its repurposing challenging, galantamine was globally launched as an Alzheimer's disease drug in 2000. Many other possible uses have been clinically investigated, and might yet develop into another drug career. This case study is presented as an example for classical on-target drug repurposing and the challenges that such a project can face.

Keywords: Alzheimer’s disease; cholinesterase inhibitors; drug repositioning; galantamine; intellectual property.

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.


<b>Figure 1.</b>
Figure 1.. Galantamine.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles


    1. Proskurnina NF, Areshknina LY. J. Chim. Gen. USSR. Chem. Abst. 1947;1948;1742(1595h):1216. No title available. (Russian), and. English.
    1. Proskurnina NF, Yakovieva A. Ob alkaloidakh Galanthus woronowi. 2. O vydelenii novogo alkaloida. Zhurnal Obshchei Khimii. J. Gen. Chem. USSR. Chem. Abst. 1952;1953;2247(10):1899–1902. 6959c. (Russian), and.
    1. Uyeo S, Kobayashi S. Lycoris alkaloids. XXIV. Isolation and characterization of lycoremine. Pharm. Bull. 1953;1(2):139–142. - PubMed
    1. Heinrich M, Lee Teoh H. Galanthamine from snowdrop – the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. J. Ethnopharmacol. 2004;92(2–3):147–162. - PubMed
    1. Irwin RL, Smith HJ., 3rd Cholinesterase inhibition by galanthamine and lycoramine. Biochem. Pharmacol. 1960;3:147–148. - PubMed

LinkOut - more resources